Capricor Therapeutics Set to Join Russell 2000® and Russell 3000® Indexes
July 01, 2024 09:00 ET
|
Capricor Therapeutics
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...
Capricor Therapeutics Announces Long-Term Benefit of Deramiocel (CAP-1002) in Both Skeletal Muscle and Cardiac Function in the HOPE-2 OLE Study in Duchenne Muscular Dystrophy
June 28, 2024 09:00 ET
|
Capricor Therapeutics
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating...
CORRECTION: Capricor Therapeutics
June 25, 2024 10:30 ET
|
Capricor Therapeutics
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by...
Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy
June 25, 2024 08:30 ET
|
Capricor Therapeutics
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
June 11, 2024 09:25 ET
|
Capricor Therapeutics
--FDA Grants Pre-BLA Meeting Request and Rolling BLA Submission after Review of HOPE-2 and HOPE-2 OLE 3-Year Results-- SAN DIEGO, June 11, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics...
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
June 04, 2024 09:00 ET
|
Capricor Therapeutics
--Results in Performance of the Upper Limb (PUL 2.0) Continue to Show Benefits in Skeletal Muscle Function After 3 Years of CAP-1002 Treatment (p< 0.001)-- --Stabilization in Left Ventricular...
Capricor Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024 16:05 ET
|
Capricor Therapeutics
–Phase 3, HOPE-3 Trial (Cohort A) of CAP-1002 in Duchenne Muscular Dystrophy Fully Enrolled; On Track to Report Top-Line Data in Q4 2024– –Positive Type-B CMC FDA Meeting held in Q1; Company Aligned...
Capricor Therapeutics to Present Exosome Platform Updates at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
May 09, 2024 09:15 ET
|
Capricor Therapeutics
-Preclinical findings show exosome-based therapeutic approach for the treatment of arginase-1 deficiency (ARG1-D)- -Presentation to be featured in an oral session being held on May 9, 2024- SAN...
Capricor Therapeutics to Present at Upcoming Scientific and Medical Conferences
May 08, 2024 09:00 ET
|
Capricor Therapeutics
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...
Capricor Therapeutics to Present First Quarter 2024 Financial Results and Recent Corporate Update on May 13
May 06, 2024 09:00 ET
|
Capricor Therapeutics
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare...